April 17, 2007
Beckman Coulter has entered into an agreement to acquire all of Biosite Inc’s outstanding stock in a deal valued at approximately $1.55 billion.
The biomedical company that commercializes proteomics discoveries has had a relationship with Beckman Coulter for four years
The deal will increase the company’s presence in providing immunoassay tests, and will expand the market opportunity for Biosite’s Triage family of diagnostic products.
Biosite’s board of directors unanimously voted to recommend that shareholders tender their shares in this offer. The transaction is expected to close in the second quarter.
For more information, visit Beckman Coulter online.
